From 21 weeks to 12, with zero variation

New Product Introduction at Janssen Biologics, Ringaskiddy. Delivered with a cross-functional team, via Life Science Associates.

The stakes

In biologics, the commercial clock starts at molecule declaration, not at approval. Every week between declaring a molecule and producing the first batch of clinical-grade material is a week taken off the patent-protected window at the far end of the product’s life, where revenue is highest and biosimilar competition has not yet arrived. The decision that governs that clock sits at the manufacturing site: how fast, and how reliably, can it take a molecule from declaration to first GMP production. Around that period the surrounding development phase commonly ran twelve to fifteen months or more. A site that could compress and stabilise its own part of the pipeline changed what the whole clinical organisation could attempt.

The situation

By 2012 the Janssen Biologics site at Ringaskiddy, County Cork faced a change of mission. A roughly half-billion-euro facility built to manufacture two or three commercial products now had to become a multi-product introduction engine: taking molecules from lab scale to clinical supply and running several programmes in parallel. The starting point was a 21-week cycle from declaration to first production, with high variability and a long tail of programmes that ran well beyond that. The cause was not a shortage of data or systems. It was the process itself: too many handoffs, unclear ownership, too little standardisation across the steps from technology transfer to GMP production. With a cycle that unpredictable, the site could not commit to a portfolio with any confidence.

The work

In 2012, Kinetica was brought in to redesign that process, working with a cross-functional team drawn from across the site. The approach was deliberately unglamorous: map the real flow from technology transfer to first production, find where the handoffs and ambiguities lived, remove what could be removed, and give the remaining steps clear ownership and a standard way of running. The aim was never a single faster run. It was a process that produced the same result every time, so the next molecule, and the one after that, could be planned around it. The first introduction through the redesigned process completed within a year of starting.

The result

The cycle came down from 21 weeks to 12, a 43% reduction. More important than the average was the variability. The redesigned process delivered every product on time, every time, removing the thirty-week-plus outliers that had made portfolio planning impossible. A predictable cycle is a different kind of asset from a fast one. It let the site commit to several parallel introductions, and the portfolio grew from two commercial products to five, alongside a widening clinical pipeline. Ringaskiddy was later designated a global Centre of Excellence for clinical drug substance, and the same principles were carried into the redesign of the wider technology-transfer process across the biologics network. In 2020 the World Economic Forum named the site a Global Lighthouse, citing accelerated technology transfer, the public face of the work that had made introductions both fast and predictable.

Why it mattered

The second molecule through the redesigned process was daratumumab, now marketed as Darzalex. Licensed in 2012 and approved by the FDA in 2015, it has since become Johnson & Johnson’s single largest product. Manufacturing readiness did not approve that drug, and it would be wrong to claim it did: clinical, regulatory and enrolment timelines all had their own constraints. What a fast, zero-variation introduction process did was remove manufacturing as a bottleneck, so the clinical and regulatory teams could move at their own maximum pace and the site could supply a growing portfolio without holding anything up.

That is the shape of the value. Weeks recovered at the start of development are felt at the tail of the revenue curve, in the protected years where each week is worth the most, and the reliability is felt across every programme the site can then confidently take on.

The capability was never one decision made well. It was a process that made a recurring class of decisions well, repeatedly, and could be planned around. That is the work.